Macdiarmid SA
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. [Journal Article]
Rev Urol 2009; 11(1):1-6.
Multiple antimuscarinic agents are available for the treatment of overactive bladder. Many of the agents have undergone reformulation in an attempt to improve patient adherence and drug tolerability. Oxybutynin evolved from an immediate-release pill to a once-daily oral preparation, and is now available as a transdermal patch and gel. This article discusses the clinical impact of oxybutynin reformulation and reviews the evolution and benefits of transdermal therapy.
More from this journal |
